Stock Ratings / Health Care / PHAR / options

CRVS (31) IVA (61) ALMS (23) OBX (39) ⌘ Pro Terminal →

Pharming Group N.V. ADS each representing 10 (PHAR) Options Positioning, Max Pain & Unusual Sweeps

$12.13 -1.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pharming Group N.V. ADS each representing 10 (PHAR) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $856.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHAR)Realized 20D OHLCV Swing Band: ±7.1%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±7.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PHAR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PHAR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PHAR)

✓Walkthrough of PHAR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PHAR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.62%📐 HORIZONTAL RANGE

2026-10-30O $12.20H $12.31L $12.09C $12.13VOL 14.0K

RES: $17.85SUP: $9.03SMA50: $10.71SMA200: $13.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PHAR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PHAR Butterfly Map → + Track PHAR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PHAR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PHAR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PHAR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHAR)

Health Care Rank #229 of 1016 ⚔️ CRVS vs PHAR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PHAR vs. CRVS, IVA, ALMS, OBX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pharming Group N.V. ADS each representing 10 (PHAR) ranks #229 by composite RQD confidence (58/100, grade D+) and #381 by equity capitalization ($856.7M). Within this direct 5-issuer industry benchmark cohort, PHAR leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with PHAR at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PHAR ACTIVE Pharming Group N.V. ADS each representing 10	D+	58/100	—	—	—	-1.06%	$856.7M	Benchmark Subject
CRVS Corvus Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-2.76%	$860.6M	/crvs-vs-phar →
IVA Inventiva S.A. American Depository Shares	C-	61/100	—	—	—	+0.54%	$881.3M	/iva-vs-phar →
ALMS Alumis Inc.	E	23/100	—	—	-35.0%	-3.37%	$891.8M	/alms-vs-phar →
OBX Obsidian Therapeutics Inc.	D-	39/100	—	—	-35.0%	-0.48%	$896.9M	/obx-vs-phar →

2. PHAR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Pharming Group N.V. ADS each representing 10 (PHAR) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $856.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PHAR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PHAR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pharming Group N.V. ADS each representing 10 (NASDAQ: PHAR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $12.13 (-1.06% 1D, market cap $856.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHAR ranks #229 in composite RQD confidence.

How does PHAR compare to CRVS and IVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHAR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRVS (Corvus Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $860.6M) and IVA (Inventiva S.A. American Depository Shares) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, PHAR leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PHAR?

For Pharming Group N.V. ADS each representing 10 (PHAR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #229 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PHAR trading relative to its 50-day, 200-day, and 52-week technical levels?

PHAR last traded at $12.13 (-1.06% on volume of 12,429 shares), positioning the stock +13.26% above its 50-day simple moving average ($10.71) and -11.97% below its 200-day simple moving average ($13.78). Across its 52-week range of $9.11 to $21.34, PHAR sits at the 24.7% percentile with a 14-day RSI of 70.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±7.1% ($11.27 to $12.99).